Brokerages Anticipate Stealth BioTherapeutics Corp (NASDAQ:MITO) to Announce -$0.04 EPS

Equities analysts expect that Stealth BioTherapeutics Corp (NASDAQ:MITO) will post earnings per share of ($0.04) for the current quarter, according to Zacks. Zero analysts have made estimates for Stealth BioTherapeutics’ earnings. The business is expected to announce its next quarterly earnings results on Wednesday, November 13th.

According to Zacks, analysts expect that Stealth BioTherapeutics will report full year earnings of ($0.30) per share for the current financial year, with EPS estimates ranging from ($0.34) to ($0.25). For the next financial year, analysts expect that the firm will post earnings of ($0.20) per share, with EPS estimates ranging from ($0.26) to ($0.13). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Stealth BioTherapeutics.

Stealth BioTherapeutics (NASDAQ:MITO) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.04.

Several research analysts recently commented on MITO shares. Jefferies Financial Group set a $9.00 price target on Stealth BioTherapeutics and gave the company a “hold” rating in a research report on Tuesday, October 15th. Cantor Fitzgerald started coverage on Stealth BioTherapeutics in a research report on Friday, September 27th. They set an “overweight” rating and a $18.00 price target for the company. Nomura set a $28.00 price target on Stealth BioTherapeutics and gave the company a “buy” rating in a research report on Friday, October 18th. Zacks Investment Research cut Stealth BioTherapeutics from a “buy” rating to a “sell” rating in a research report on Wednesday, October 16th. Finally, HC Wainwright set a $21.00 price target on Stealth BioTherapeutics and gave the company a “buy” rating in a research report on Friday, October 18th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $21.86.

NASDAQ MITO traded down $0.13 during trading hours on Wednesday, hitting $6.29. 2,500 shares of the company traded hands, compared to its average volume of 21,823. The business’s 50-day moving average is $6.81 and its 200-day moving average is $11.13. Stealth BioTherapeutics has a twelve month low of $4.97 and a twelve month high of $20.99. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.13 and a current ratio of 2.13. The stock has a market capitalization of $231.20 million and a price-to-earnings ratio of -4.46.

Stealth BioTherapeutics Company Profile

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

Further Reading: Is it better to buy a fund with a higher or lower NAV?

Get a free copy of the Zacks research report on Stealth BioTherapeutics (MITO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.